Drugmaker Perrigo (PRGO) beat Wall Street’s fiscal Q4 expectations Thursday, sending the stock sharply higher even though its fiscal 2015 guidance missed estimates. The stock rose 10.14 to 149.29, reclaiming its 50-day moving average in double the normal volume. Perrigo has lost its leadership status within the stock market, yet it still serves as a bellwether for the generics and nutritionals industry.